Literature DB >> 15020653

Antagonism of the alpha4 integrin subunit attenuates the acute inflammatory response to stent implantation yet is insufficient to prevent late intimal formation.

Xiaoli Ma1, Edward R O'Brien.   

Abstract

Mononuclear leukocytes infiltrate the artery wall via integrin-mediated mechanisms and play an integral role in intimal formation after stenting. We sought to determine if acute antagonism of the alpha4 subunit of very late antigen-4 is sufficient for the late attenuation of stent intimal area (IA). Twenty-four hypercholesterolemic rabbits underwent iliac artery balloon injury, followed 2 weeks later by stent implantation, and the animals were randomized to receive an anti-alpha4 antibody (HP1/2) or a nonspecific isotypic control immunoglobulin (1E6) intravenously 1 h before stenting. Compared with controls, HP1/2-treated rabbits showed 50%, 51%, and 44% reductions in the percentage on intimal cells that were macrophages on days 3, 7, and 28 after stenting and a 59% reduction in intimal proliferation on day 3. Although stent IA was reduced by 63% and 48% in the antibody-treated group compared with the control group on days 3 and 7, this difference was not present on day 28. These data highlight the need for sustained, anti-inflammatory therapies for the prevention of stent intimal formation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15020653     DOI: 10.1189/jlb.1203618

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  2 in total

Review 1.  Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords?

Authors:  Roberto González-Amaro; María Mittelbrunn; Francisco Sánchez-Madrid
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

2.  Contribution of recipient-derived cells in allograft neointima formation and the response to stent implantation.

Authors:  Xiaoli Ma; Benjamin Hibbert; Dawn White; Richard Seymour; Stewart C Whitman; Edward R O'Brien
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.